Monthly Archives: January 2008
It's Not Just Vytorin. Now Statins are Under Fire
The follow-up to this week’s Vytorin flap has taken an ominous twist. And I’m not just thinking of threatened investigations and lawsuits. A handful of relatively prestigious publications have moved past criticizing Vytorin, Merck, and Schering-Plough and have begun to ask uncomfortable questions about statins in general and the whole idea of lowering cholesterol. In [...]
Posted in R&D 4 Comments
EU Antitrust Officials Raid Pharma Companies
European news sources are reporting that European Union officials conducted surprise dawn raids Wednesday at the offices of a number of pharmaceutical companies, including Pfizer, GlaxoSmithKline, Sanofi-Aventis, AstraZeneca, Merck Sharp & Dohme, Johnson & Johnson’s Belgian unit, Wyeth, and Novartis’ Sandoz division.
What’s the beef? Reports say the EU is looking for evidence of [...]
Posted in Legal, Regulatory 1 Comment
Pharm Exec News ·Â January 17, 2008
Here are this week’s top news stories, as reported on PharmExec.com:
More Prescriptions Through Learning: The Doctor’s Choice
New report finds that neither sales reps nor patient requests are the deciding factor when it comes to physician prescribing habits, information is—the more the better.
Click to read>>>
(2)008: Licensed to Sell
Sales representatives will now need a license to [...]
Posted in Marketing Leave a comment
Pharma Buzz Noticeably Absent at JPMorgan's 2008 Healthare Conference
We didn’t get to travel to this year’s JPMorgan Healthcare Conference, but Pharm Exec contributor Audrey S. Erbes (founder of Erbes & Associates) did. Here are her impressions:
There was a lack of usual excitement among drug companies but no sense of distress.
Although this year’s event broke attendance records with more than 7,700 participants and 331 [...]
Posted in Deals, Meetings Leave a comment

TMC125: Tick, Tock, Tick, Tock